62972-70-7

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 13 carbon (C) atoms, 19 hydrogen (H) atoms, 3 nitrogen (N) atoms, and 1 oxygen (O) atom.

Explanation

The molecular weight is the mass of one mole of a substance, measured in grams per mole (g/mol). For 1-(4-AMINO-PHENYL)-3-CYCLOHEXYL-UREA, the molecular weight is 229.31 g/mol.

Explanation

The appearance of a chemical compound refers to its physical state and color. In this case, the compound is a white solid, which means it is a solid at room temperature and appears white in color.

Explanation

Functional groups are specific groups of atoms within a molecule that have characteristic chemical properties and reactivity. In 1-(4-AMINO-PHENYL)-3-CYCLOHEXYL-UREA, the urea derivative is the main functional group, with a cyclohexyl group and an amino-phenyl group attached to it.

Explanation

The biological activities of a compound refer to its effects on living organisms. In this case, 1-(4-AMINO-PHENYL)-3-CYCLOHEXYL-UREA has potential anti-cancer and anti-inflammatory properties, which means it may be useful in the development of pharmaceuticals for treating cancer and inflammation.

Explanation

As a potential drug candidate, 1-(4-AMINO-PHENYL)-3-CYCLOHEXYL-UREA may be further researched and developed for use in the pharmaceutical industry, particularly for the treatment of cancer and inflammation.

Explanation

In addition to its potential pharmaceutical applications, 1-(4-AMINO-PHENYL)-3-CYCLOHEXYL-UREA can also be used as a building block in chemical research and synthesis. This means it can be used to create other compounds with potentially useful properties or applications.

Molecular Weight

229.31 g/mol

Appearance

White solid

Functional Groups

Urea derivative, cyclohexyl group, and amino-phenyl group

Biological Activities

Potential anti-cancer and anti-inflammatory properties

Application in Pharmaceuticals

Potential drug candidate

Application in Chemical Research and Synthesis

Building block for the creation of other compounds

Upstream product

• 3173-53-3 Cyclohexyl isocyanate 
• 106-50-3 1,4-phenylenediamine 
• 100-01-6 4-nitro-aniline 
• 53015-89-7 4-nitrophenyl isocyanurate 
• 108-91-8 cyclohexylamine 
• 100-28-7 4-Nitrophenyl isocyanate 
• 75461-45-9 1-(4-nitrophenyl)-3-cyclohexylurea 

Downstream Products

• 1355964-27-0 C₂₈H₃₆N₆O₂ 

Relevant academic research and scientific papers

Enzymatic hydrolysis-induced degradation of a lactose-coupled supramolecular hydrogel

Amphiphilic urea 1 with a hydrophilic lactose group was prepared as a low-molecular-weight hydrogelator, which formed a transparent supramolecular hydrogel. Enzymatic hydrolysis of the lactose moiety using β-galactosidase allowed a gel-to-sol phase transition of the supramolecular hydrogel. A β-galactosidase inhibitor enables us to control the time course of this phase transition.

Discovery of novel 2,4-disubstituted pyrimidines as Aurora kinase inhibitors

In order to explore novel Aurora kinase inhibitors, a series of novel 2,4-disubstituted pyrimidines were designed, synthesized and evaluated their in vitro anti-proliferative activities against a panel of cancerous cell lines (A549, HCT-116 and MCF-7). Among them, compound 12a showed the moderate to high anti-proliferative activities against A549 (IC50 = 12.05 ± 0.45 μM), HCT-116 (IC50 = 1.31 ± 0.41 μM) and MCF-7 (IC50 = 20.53 ± 6.13 μM) cells, as well as the Aurora A and Aurora B inhibitory activities with the IC50 values of 309 nM and 293 nM, respectively. Furthermore, compound 12a induced apoptosis by upregulated the pro-apoptotic proteins Bax and decreased the anti-apoptotic protein Bcl-xl in HCT-116 cells. Moreover, the molecular docking study showed that compound 12a had good binding modes with Aurora A and Aurora B and the bioinformatics prediction discovered that compound 12a exhibited good drug likeness using SwissADME. Taken together, these results indicated that 12a may be a potential anticancer compound that was worthy of further development as Aurora kinase inhibitor.

NOVEL HYDROGELATOR

A novel hydrogelator that contains a monourea compound having a sugar structure, which can be produced by a simple method, includes a compound of the following Formula [1]: (wherein Sg is a sugar group, A is a divalent linking group, and R is a

A new class of low-molecular-weight amphiphilic gelators

A new powerful class of low-molecular-weight amphiphilic compounds has been synthesized and their structure-property relationships with respect to their gelation ability of organic solvents have been investigated. These compounds are able to gel organic solvents over a broad range of polarity. Especially polar solvents such as valeronitrile and γ-butyrolactone can be gelled even at concentrations far below 1 wt %. It was found that the gelation ability of these asymmetrically substituted p-phenylendiamines depends on a well-balanced relation of the terminal head group, the units involved in hydrogen bonding (amide or urea groups), and on the length of the alkyl chain. With this class of new gelators it is possible to tailor thermal and mechanical properties in different organic solvents and open various application possibilities.

Structural refinement of inhibitors of urea-based soluble epoxide hydrolases

The soluble epoxide hydrolase (sEH) is involved in the metabolism of arachidonic, linoleic, and other fatty acid epoxides, endogenous chemical mediators that play an important role in blood pressure regulation and inflammation. 1,3-Disubstituted ureas, carbamates, and amides are new potent and stable inhibitors of sEH. However, the poor solubility of the lead compounds limits their use. Inhibitor structure-activity relationships were investigated to better define the structural requirements for inhibition and to identify points in the molecular topography that could accept polar groups without diminishing inhibition potency. Results indicate that lipophilicity is an important factor controlling inhibitor potency. Polar groups could be incorporated into one of the alkyl groups without loss of activity if they were placed at a sufficient distance from the urea function. The resulting compounds had a 2-fold higher water solubility. These findings will facilitate the rational design and optimization of sEH inhibitors with better physical properties.